3/28
09:16 am
obio
Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Low
Report
Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
3/27
04:17 pm
obio
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
Low
Report
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
3/26
08:00 am
obio
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
Medium
Report
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
3/13
08:00 am
obio
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
Low
Report
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
3/7
08:00 am
obio
Orchestra BioMed to Participate in Upcoming Investor Conferences
Medium
Report
Orchestra BioMed to Participate in Upcoming Investor Conferences
3/6
08:37 am
obio
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
Low
Report
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
2/26
08:00 am
obio
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
Low
Report
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years